Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 13/20 | 0.50 |
| ▸ | RAPGEF3 | O95398 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19997309 | 0.79 | HIF1A (0.54) | HIF1A | |
| SCHEMBL6519681 | 0.79 | HIF1A (0.54) | HIF1A | |
| SCHEMBL31173500 | 0.79 | HIF1A (0.54) | HIF1A | |
| SCHEMBL8880493 | 0.78 | HIF1A (0.53) | HIF1A | |
| SCHEMBL15902003 | 0.76 | HIF1A (0.55) | HIF1A | |
| SCHEMBL496601 | 0.74 | HIF1A (0.65) | HIF1A | |
| SCHEMBL2907438 | 0.73 | HIF1A (0.58) | HIF1A | |
| SCHEMBL1809709 | 0.73 | HIF1A (0.58) | HIF1ARAPGEF3 | |
| SCHEMBL29580724 | 0.73 | HIF1A (0.58) | HIF1A | |
| SCHEMBL3434886 | 0.73 | HIF1A (0.61) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124489-B2 | EPAC antagonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200255388-A1 | EPAC ANTAGONISTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-13 | — | — | US | disclosed |
| EP-1001941-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS KYNURENINE-3-HYDROXYLASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006375-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS KYNURENINE-3-HYDROXYLASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255388-A1 | EPAC ANTAGONISTS | EPAS1, GPR139, CRACR2A | KCNH2 1280/4885HIF1A 1159/4885RAPGEF3 5/4885 |
| US-11124489-B2 | EPAC antagonists | EPAS1, GPR139, CRACR2A | KCNH2 1280/4885HIF1A 1159/4885RAPGEF3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.